newsfilter
← Latest News
GlobeNewswire·

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways SP-3164 targeted protein degrader